Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accelrys announces launch of ScienceCloud
ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable, cloud-based scientific platform. With no software to manage and no hardware to
ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable, cloud-based scientific platform. With no software to manage and no hardware to
Big Brand Media and Axxess Pharma/AllStar Health Brands are proud to be stepping into the supplement ring with one of the biggest names in mixed martial arts by
Previously, FACTS was jointly developed and owned by Berry Consultants and Tessella, but this agreement gives Berry Consultants full ownership of the software. FACTS allows biostatisticians and clinical
US patent No. 8,642,564 provides methods for oral delivery of nucleotide-oligomer analogs including anti-sense and RNA interference drugs. Such drugs represent an important new class of therapeutics but
This patent provides for once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5a-reductase to patients with nodulocystic and conglobate acne vulgaris.
The trials will be conducted under the supervision of GRU Cancer Center director and former chief of the Vaccines Section at the National Cancer Institute Dr Samir Khleif.
Regulus will lead development of its fibrosis program targeting microRNA-21 (miR-21) for the treatment of Alport Syndrome, an orphan, life-threatening genetic kidney disease with no approved therapy, and
In the light of these results, Ipsen announces its intention to file the first ready-to-use liquid toxin A in Europe and in the Rest of the World (ROW).
The application covers a system and method of controlling Parkinson’s therapy in response to motor symptoms. The allowed claims include a portable system for measuring, quantifying, and treating
The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through the first quarter of 2014, valued at $1.1m. The